In a study published in Cell, Dr. Hans Clevers, CSO of HUB, has demonstrated that the heterogeneity of breast cancer subtypes can be captured using patient derived Organoid cultures. This new Organoid cancer model system can strongly support effective drug development and facilitates the link between clinical and laboratory data. This publication was also picked up by national newspaper De Volkskrant with the key message that this new system could help speed up drug development considerably while also saving money.
You can read the full publication in Cell here (login required):
The interview with Dr. Hans Clevers on this publication in Dutch daily newspaper De Volkskrant is available online here: